NHS England Approves Life-Extending Breast Cancer Treatment Enhertu Following Years of Campaigning

Patients across England diagnosed with a specific form of incurable breast cancer will now be able to access the life-prolonging medication Enhertu through the National Health Service. The decision comes two years after the treatment was initially blocked by health authorities on the grounds that it was too expensive.

The therapy offers significant clinical benefits for people diagnosed with HER2-low metastatic breast cancer, providing an average survival extension of nearly seven months. In some cases, clinical evidence shows that patients can live up to three years longer while receiving the treatment.

Beginning on Thursday, doctors in England have been granted clearance to prescribe the drug to eligible individuals, a group estimated at approximately 1,000 women annually. While health authorities in Wales are anticipated to adopt similar prescribing measures in the near future, the newly updated guidance does not automatically take effect in Northern Ireland.

The move resolves a major geographic disparity in care across the United Kingdom. Patients in Scotland have been able to obtain Enhertu on their regional NHS since 2023, while individuals in 26 other European nations have also had routine access to the therapy.

Charities, healthcare advocates, and terminal patients had mounted extensive public campaigns demanding wider availability after the National Institute for Health and Care Excellence (NICE) concluded in 2024 that the medication did not represent sufficient value for money.

Health Secretary Yvette Cooper praised the dedication of those who pushed for the change, describing Enhertu as potentially life-changing. She noted that the new recommendation ensures NHS patients will at last receive the treatment, describing the outcome as a tribute to the campaigners and charitable organisations who refused to abandon their efforts.

Charity leaders, however, underscored the heavy emotional toll and loss of life that occurred during the prolonged regulatory delay. Claire Rowney, the chief executive of Breast Cancer Now, acknowledged the successful outcome while emphasizing that the victory is clouded by the fact that thousands missed out on the drug and many died while waiting for approval.

Rowney urged systemic changes across the healthcare landscape, calling on the government, NICE, NHS England, and pharmaceutical manufacturers to reform the current evaluation structure so that patients with incurable secondary breast cancer do not have to expend their limited remaining time lobbying for access to life-extending therapies.

Among those directly affected by the policy change is Kate Wills, a 51-year-old mother and professional who is living with HER2-low metastatic breast cancer that has spread to her lungs and bones. Wills expressed overwhelming relief and joy upon learning she could finally access the treatment, describing it as an immense source of hope after enduring the painful knowledge that an effective drug existed but was out of reach.

With two children in their teens and early twenties, Wills had previously focused on living long enough to see her youngest child complete school. With the approval of Enhertu, she shared that she can now dare to dream of surviving to witness major future milestones, including watching her children fall in love and get married.

Even so, Wills described the breakthrough as bittersweet, noting that her immediate thoughts turned toward the friends and fellow patients who passed away before the NHS made the treatment accessible.

One of those advocates was Jeannie Ambrose, who spoke publicly about her situation two years ago when she was 53. Ambrose had argued passionately that terminally ill individuals should be spending their remaining days enjoying life with family and friends rather than using their energy to campaign for essential treatments. Ambrose died in January of this year.

The policy reversal by NICE did not occur because the drug's manufacturers, Daiichi Sankyo and AstraZeneca, agreed to make substantial reductions to their prices. Instead, the shift stems primarily from a trade pact reached with the United States in which the UK government committed to increasing overall expenditure on pharmaceuticals by 25 percent.

Following that agreement, NICE raised its spending thresholds regarding the value of a Quality-Adjusted Life Year (QALY), which measures the monetary value placed on an additional year of good health. The upper limit for a QALY was raised from £30,000 to £35,000.

In addition to the revised monetary limits, NICE introduced a more nuanced assessment model at the end of August to evaluate patient quality of life. Together with persistent pressure from advocacy groups, these regulatory adjustments altered the cost-benefit calculations in favour of approving the medication.

Pharmaceutical manufacturers welcomed the updated guidance. AstraZeneca called for sustained collaboration across the health system to ensure speedier and more equitable access to treatments going forward, while Helen Knight, the director of medicines evaluation at NICE, expressed satisfaction that a commercial solution had finally been secured to deliver the therapy to patients.